Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma
HIV is still a major public health problem. At present, HIV-associated lymphoma remains the leading cause of deaths among people living with HIV, which should be paid more attention to. 18F-fluorodeoxglucose (FDG) PET/CT has been recommended in the initial staging, restaging, response assessment and...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1117064/full |
| _version_ | 1797942537935126528 |
|---|---|
| author | Qi Liu Tao Yang Xiaoliang Chen Yao Liu |
| author_facet | Qi Liu Tao Yang Xiaoliang Chen Yao Liu |
| author_sort | Qi Liu |
| collection | DOAJ |
| description | HIV is still a major public health problem. At present, HIV-associated lymphoma remains the leading cause of deaths among people living with HIV, which should be paid more attention to. 18F-fluorodeoxglucose (FDG) PET/CT has been recommended in the initial staging, restaging, response assessment and prognostic prediction of lymphomas in general population. HIV-associated lymphoma is, however, a different entity from lymphoma in HIV-negative with a poorer prognosis. The ability to accurately risk-stratify HIV-infected patients with lymphoma will help guide treatment strategy and improve the prognosis. In the review, the current clinical applications of 18F-FDG PET/CT in HIV-associated lymphoma will be discussed, such as diagnosis, initial staging, response evaluation, prognostic prediction, PET-guided radiotherapy decision, and surveillance for recurrence. Moreover, future perspectives will also be presented. |
| first_indexed | 2024-04-10T20:10:04Z |
| format | Article |
| id | doaj.art-57b9a2025ab34ee09bf19f9a9e5251e7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T20:10:04Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-57b9a2025ab34ee09bf19f9a9e5251e72023-01-26T13:43:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011310.3389/fonc.2023.11170641117064Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphomaQi Liu0Tao Yang1Xiaoliang Chen2Yao Liu3Department of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, ChinaDepartment of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, ChinaHIV is still a major public health problem. At present, HIV-associated lymphoma remains the leading cause of deaths among people living with HIV, which should be paid more attention to. 18F-fluorodeoxglucose (FDG) PET/CT has been recommended in the initial staging, restaging, response assessment and prognostic prediction of lymphomas in general population. HIV-associated lymphoma is, however, a different entity from lymphoma in HIV-negative with a poorer prognosis. The ability to accurately risk-stratify HIV-infected patients with lymphoma will help guide treatment strategy and improve the prognosis. In the review, the current clinical applications of 18F-FDG PET/CT in HIV-associated lymphoma will be discussed, such as diagnosis, initial staging, response evaluation, prognostic prediction, PET-guided radiotherapy decision, and surveillance for recurrence. Moreover, future perspectives will also be presented.https://www.frontiersin.org/articles/10.3389/fonc.2023.1117064/fullHIVdiffuse large B-cell lymphomaBurkitt’s lymphomaHodgkin’s lymphoma18F-FDG PET |
| spellingShingle | Qi Liu Tao Yang Xiaoliang Chen Yao Liu Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma Frontiers in Oncology HIV diffuse large B-cell lymphoma Burkitt’s lymphoma Hodgkin’s lymphoma 18F-FDG PET |
| title | Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma |
| title_full | Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma |
| title_fullStr | Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma |
| title_full_unstemmed | Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma |
| title_short | Clinical value of 18F-FDG PET/CT in the management of HIV-associated lymphoma |
| title_sort | clinical value of 18f fdg pet ct in the management of hiv associated lymphoma |
| topic | HIV diffuse large B-cell lymphoma Burkitt’s lymphoma Hodgkin’s lymphoma 18F-FDG PET |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1117064/full |
| work_keys_str_mv | AT qiliu clinicalvalueof18ffdgpetctinthemanagementofhivassociatedlymphoma AT taoyang clinicalvalueof18ffdgpetctinthemanagementofhivassociatedlymphoma AT xiaoliangchen clinicalvalueof18ffdgpetctinthemanagementofhivassociatedlymphoma AT yaoliu clinicalvalueof18ffdgpetctinthemanagementofhivassociatedlymphoma |